Lv65
2255 积分 2022-06-06 加入
HR+/HER-2-早期乳腺癌复发风险与临床管理专家共识（2025版）
1天前
已完结
乳腺癌分子病理检测临床实践指南（2025版）
2天前
已完结
Trop-2 expression and the tumor immune microenvironment in cervical cancer
7天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
8天前
已完结
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
1个月前
已关闭
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
2个月前
已完结
Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC
9个月前
已关闭
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
9个月前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
9个月前
已完结
皖公网安备34019202002308
